At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Aug 13, 2026 at 07:30 ET
Abeona reported Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ, with five patients treated. However, EPS of -$0.35 missed the consensus estimate of -$0.24 by 45.8%, and the net loss widened to -$20.2M from -$17.1M in Q1, driven by a $7.2M non-cash warrant liability charge. The CMS NTAP designation for ZEVASKYN effective October 2026 is a positive catalyst, but the EPS miss and ongoing cash burn temper the outlook.
- Q2 2026 net ZEVASKYN revenue of $11.4M, up 31% QoQ from $8.7M in Q1 2026.
- Five patients treated with ZEVASKYN in Q2; revenue recognized for four due to one batch below threshold.
- EPS of -$0.35 missed consensus estimate of -$0.24 by 45.8%.
- Net loss widened to -$20.2M from -$17.1M in Q1, including a $7.2M non-cash warrant liability charge.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access